The U.S. Food and Drug Administration (FDA) has granted orphan drug and rare pediatric disease designations to ART4, an experimental therapy for Alagille syndrome…
News
A gene-editing therapy designed to specifically inactivate a hidden genetic blueprint of the hepatitis B virus (HBV) — the cause of hepatitis B —…
CHOLANGITIS
NewsNew trial data show saroglitazar works to ease liver damage in PBC
One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…
CHOLESTASIS
NewsNew medications show promise for children with rare liver disease
While different types of progressive familial intrahepatic cholestasis (PFIC) vary in their genetic cause and clinical profile, new medications like Bylvay (odevixibat) and Livmarli…
BILIARY ATRESIA
NewsAge at Kasai, spleen issues key to biliary atresia outcomes
Babies who had standard Kasai surgery when they were more than 60 days old or had spleen malformations were more likely to have poor outcomes…
HEPATITIS
NewsCanada clears fast fingerstick test for hepatitis C
A one-hour point-of-care test for hepatitis C has been cleared for use in Canada, which could help accelerate diagnosis and monitor how people with…
CHOLANGITIS
NewsBlood marker can predict liver function improvement in PBC
A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent…
CHOLESTASIS
NewsTargeting mitochondrial problems eases cholestasis in mouse model
Problems in mitochondria, the cell’s powerhouses, may contribute to liver damage associated with cholestasis and represent a potential therapeutic target, a study showed. Deteriorating…
FATTY LIVER DISEASE
NewsDrug for fatty liver disease MASH may help prevent transplants
Regulators in the European Union (EU) have granted conditional approval to Rezdiffra (resmetirom) for some people with metabolic dysfunction-associated steatohepatitis (MASH), making it the first…
FATTY LIVER DISEASE
NewsFDA gives conditional approval to Wegovy for some liver patients
The U.S. Food and Drug Administration (FDA) has conditionally approved Novo Nordisk’s Wegovy (semaglutide) to treat certain people with metabolic dysfunction-associated steatohepatitis (MASH), a…
Recent Posts
- Understanding the connection between type 2 diabetes and fatty liver disease
- After months of anticipation, the first day of kindergarten finally arrived
- What my teenager teaches me about finding my voice and speaking up
- If you’re going to be in the hospital, here’s some things to keep in mind
- Back-to-school shopping is complicated by Alagille syndrome